Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 0.65 |
| ▸ | CDK4 | P11802 | 2/20 | 0.56 |
| ▸ | CCND1 | P24385 | 2/20 | 0.56 |
| ▸ | CCND2 | P30279 | 2/20 | 0.56 |
| ▸ | CCND3 | P30281 | 2/20 | 0.56 |
| ▸ | SYK | P43405 | 2/20 | 0.48 |
| ▸ | BTK | Q06187 | 5/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | LYN | P07948 | 1/20 | 0.47 |
| ▸ | TEC | P42680 | 1/20 | 0.47 |
| ▸ | TXK | P42681 | 1/20 | 0.47 |
| ▸ | BMX | P51813 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | CD69 | Q07108 | 1/20 | 0.47 |
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29576177 | 0.86 | CDK4 (0.58) | BRAFCDK4CCND1CCND2CCND3 | |
| SCHEMBL29575507 | 0.85 | BRAF (0.51) | BRAFSYKEGFRMAP3K5ROCK1 | |
| SCHEMBL3040980 | 0.83 | BRAF (0.69) | BRAFCDK4CCND1CCND2CCND3 | |
| SCHEMBL29370842 | 0.79 | BRAF (0.68) | BRAFEGFRJAK2JAK3IGF1R | |
| SCHEMBL29575969 | 0.79 | BRAF (0.65) | BRAFEGFRJAK2JAK3IGF1R | |
| SCHEMBL21835437 | 0.79 | BRAF (0.56) | BRAFSYKBTKEGFRMAPK1 | |
| SCHEMBL15987166 | 0.79 | BRAF (0.55) | BRAFCDK4CCND1CCND2CCND3 | |
| SCHEMBL17409829 | 0.79 | BRAF (0.55) | BRAFCDK4CCND1CCND2CCND3 | |
| SCHEMBL19533535 | 0.77 | BRAF (0.54) | BRAFCDK4CCND1CCND2CCND3 | |
| SCHEMBL3339632 | 0.77 | NPY5R (0.55) | CDK4CCND1LMNAMAPK1MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC | 2024-06-20 | — | — | US | disclosed |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2022-11-10 | — | — | US | disclosed |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | BRAF 61/4885CDK4 156/4885CCND1 1018/4885 |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | BRAF 61/4885CDK4 156/4885CCND1 1018/4885 |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | BRAF 61/4885CDK4 156/4885CCND1 1018/4885 |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | BRAF 61/4885CDK4 156/4885CCND1 1018/4885 |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | BRAF 61/4885CDK4 156/4885CCND1 1018/4885 |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | BRAF, TTK, MAP4K2 | BRAF 1/4885CDK4 358/4885CCND1 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.